Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by ImmunityBio, Inc.

< Previous 1 2 3 4 Next >
News headline image
ImmunityBio Reports Sales Momentum & Unit Growth Since Permanent J-code Issuance (J9028) in January 2025 and Financial Results for Year End 2024
From ImmunityBio, Inc.
Via Business Wire
Tickers IBRX
News headline image
ImmunityBio Receives FDA RMAT Designation for ANKTIVA® and CAR-NK for the Reversal of Lymphopenia in Patients Receiving Standard-of-Care Chemotherapy/Radiotherapy and in Treatment of Multiply Relapsed Locally Advanced or Metastatic Pancreatic Cancer
From ImmunityBio, Inc.
Via Business Wire
Tickers IBRX
News headline image
FDA Authorizes ImmunityBio to Provide Recombinant BCG (rBCG) to Urologists to Address TICE® BCG Shortage
From ImmunityBio, Inc.
Via Business Wire
Tickers IBRX
News headline image
ImmunityBio Announces UK Medicines and Healthcare Products Regulatory Agency Accepted Marketing Authorization Application for ANKTIVA® for the Treatment of Patients with BCG-unresponsive Non-Muscle Invasive Bladder Cancer Carcinoma In Situ
From ImmunityBio, Inc.
Via Business Wire
Tickers IBRX
News headline image
ImmunityBio Announces Collaboration with BeiGene on Confirmatory Phase 3 Trial of ANKTIVA® and PD-1 Checkpoint Inhibitor Combination in Non-Small Cell Lung Cancer
From ImmunityBio, Inc.
Via Business Wire
Tickers IBRX
News headline image
ImmunityBio Announces European Medicines Agency Acceptance of Marketing Authorization Application for ANKTIVA® for the Treatment of Patients with BCG-Unresponsive Non-Muscle Invasive Bladder Cancer Carcinoma In Situ
From ImmunityBio, Inc.
Via Business Wire
Tickers IBRX
News headline image
ImmunityBio Provides Regulatory Update on Anticipated FDA Submissions in 2025 Following Meeting with the Agency
From ImmunityBio, Inc.
Via Business Wire
Tickers IBRX
News headline image
ImmunityBio Provides Regulatory Update on Global Submission for ANKTIVA + BCG in BCG Unresponsive Non-Muscle Invasive Bladder Cancer with Carcinoma in situ in Europe and United Kingdom
From ImmunityBio, Inc.
Via Business Wire
Tickers IBRX
News headline image
ImmunityBio Announces Permanent J-code (J9028) for ANKTIVA® Is Now Effective
From ImmunityBio, Inc.
Via Business Wire
Tickers IBRX
News headline image
ImmunityBio, Inc. Announces Pricing of Public Offering of Common Stock
From ImmunityBio, Inc.
Via Business Wire
Tickers IBRX
News headline image
ImmunityBio, Inc. Announces Proposed Public Offering of Common Stock
From ImmunityBio, Inc.
Via Business Wire
Tickers IBRX
News headline image
ImmunityBio Completes ANKTIVA’s Post-Approval Enrollment of the 100th Patient in BCG Unresponsive NMIBC CIS Trial and Reports a Complete Response Rate of 71% with a Durable Duration of Response Ranging Up to 54 Months
From ImmunityBio, Inc.
Via Business Wire
Tickers IBRX
News headline image
ImmunityBio Reports Third-Quarter 2024 Financial Results
From ImmunityBio, Inc.
Via Business Wire
Tickers IBRX
News headline image
First Patients Dosed in Phase 1 Clinical Study of ImmunityBio’s CAR-NK Cell Therapy for the Treatment of Relapsed B-Cell Non-Hodgkin Lymphoma
From ImmunityBio, Inc.
Via Business Wire
Tickers IBRX
News headline image
ImmunityBio to Participate in the Jefferies London Healthcare Conference
From ImmunityBio, Inc.
Via Business Wire
Tickers IBRX
News headline image
ImmunityBio Presents Positive Long-Term Overall Survival Data in Non-Small Cell Lung Cancer Patients and Announces Registrational Intent Phase 3 Trials with ANKTIVA® and Checkpoint Immunotherapy at World Conference on Lung Cancer
From ImmunityBio, Inc.
Via Business Wire
Tickers IBRX
News headline image
ImmunityBio’s ANKTIVA® Now Covered By More Than a Dozen Insurance Plans Representing Over 100 Million Lives Within Months of FDA Approval
From ImmunityBio, Inc.
Via Business Wire
Tickers IBRX
News headline image
ImmunityBio Announces Study of ANKTIVA® in Combination with the AdHER2DC Cancer Vaccine as a Potential Therapy to Control Endometrial Cancer
From ImmunityBio, Inc.
Via Business Wire
Tickers IBRX
News headline image
ImmunityBio Announces Insurance Coverage of ANKTIVA® Across Multiple States with First Commercial Doses Administered Just Weeks After FDA Approval—Opening New Era for Immunotherapy Beyond Checkpoint Inhibitors
From ImmunityBio, Inc.
Via Business Wire
Tickers IBRX
News headline image
ImmunityBio Announces 2024 Annual Meeting of Stockholders with Company Update
From ImmunityBio, Inc.
Via Business Wire
Tickers IBRX
News headline image
Connecting the Dots of ANKTIVA’s Triangle Offense: A Deep Dive with Dr. Patrick Soon-Shiong and Dr. Ashish Kamat in a Three-Part UroToday Podcast
From ImmunityBio, Inc.
Via Business Wire
Tickers IBRX
News headline image
ImmunityBio Completes GMP Drug Substance Manufacturing Sufficient for 170,000 Doses of ANKTIVA®
From ImmunityBio, Inc.
Via Business Wire
Tickers IBRX
News headline image
ImmunityBio, Serum Institute of India Agree on an Exclusive Arrangement for Global Supply of Bacillus Calmette-Guerin (BCG) Across All Cancer Types
From ImmunityBio, Inc.
Via Business Wire
Tickers IBRX
News headline image
ImmunityBio Executive Chairman Dr. Patrick Soon-Shiong to Discuss ANKTIVA® Approval in Fireside Chat at the Annual Conference of the American Urological Association
From ImmunityBio, Inc.
Via Business Wire
Tickers IBRX
News headline image
ImmunityBio Announces Positive Overall Survival Results of Anktiva Combined With Checkpoint Inhibitors in Non-Small Cell Lung Cancer; Meeting Scheduled with FDA to Discuss Registration Path for ANKTIVA in Lung Cancer
From ImmunityBio, Inc.
Via Business Wire
Tickers IBRX
News headline image
ImmunityBio Announces FDA Approval of ANKTIVA®, First-in-Class IL-15 Receptor Agonist for BCG-Unresponsive Non-Muscle Invasive Bladder Cancer
From ImmunityBio, Inc.
Via Business Wire
Tickers IBRX
News headline image
ImmunityBio Quality-of-Life Study in BCG-Unresponsive Bladder Cancer Trial Indicates Improved Physical Function in the 71% Complete Responders Suggesting a Favorable Risk-Benefit Ratio for N-803 Plus BCG
From ImmunityBio, Inc.
Via Business Wire
Tickers IBRX
News headline image
ImmunityBio Announces $320 Million Investment by Oberland Capital, with $210 Million Funded at Closing, Bringing Total Financing in 2023 to $850 Million
From ImmunityBio, Inc.
Via Business Wire
Tickers IBRX
News headline image
ImmunityBio to Participate in 35th Annual Piper Sandler Healthcare Conference
From ImmunityBio, Inc.
Via Business Wire
Tickers IBRX
News headline image
First Data for ImmunityBio’s Memory Cytokine-Enriched NK Cells in Small Cell Lung Cancer at SITC Meeting Show Promising Anti-tumor Activity
From ImmunityBio, Inc.
Via Business Wire
Tickers IBRX
< Previous 1 2 3 4 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.